Nuveen Asset Management LLC Sells 29,613 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Nuveen Asset Management LLC trimmed its holdings in Inari Medical, Inc. (NASDAQ:NARI – Get Rating) by 15.3% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 164,443 shares of the company’s stock after selling 29,613 shares during the quarter. Nuveen Asset Management LLC owned about 0.31% of Inari Medical worth $11,945,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Wellington Management Group LLP increased its holdings in Inari Medical by 46.8% in the 1st quarter. Wellington Management Group LLP now owns 4,626,607 shares of the company’s stock worth $419,355,000 after buying an additional 1,475,313 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Inari Medical by 13.4% during the 1st quarter. Vanguard Group Inc. now owns 3,518,646 shares of the company’s stock valued at $318,930,000 after purchasing an additional 416,425 shares during the period. Capital International Investors grew its stake in shares of Inari Medical by 0.8% during the 1st quarter. Capital International Investors now owns 2,838,045 shares of the company’s stock valued at $257,240,000 after purchasing an additional 22,159 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Inari Medical by 22.1% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,966,302 shares of the company’s stock valued at $133,689,000 after purchasing an additional 356,309 shares during the period. Finally, Franklin Resources Inc. grew its stake in shares of Inari Medical by 1.0% during the 2nd quarter. Franklin Resources Inc. now owns 1,817,378 shares of the company’s stock valued at $123,564,000 after purchasing an additional 17,661 shares during the period. 85.19% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

NARI has been the subject of a number of recent research reports. Morgan Stanley cut their price target on Inari Medical from $95.00 to $83.00 and set an “overweight” rating for the company in a research note on Friday, January 6th. Canaccord Genuity Group boosted their price target on Inari Medical from $77.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, February 28th. Finally, Truist Financial cut their price target on Inari Medical from $75.00 to $65.00 and set a “hold” rating for the company in a research note on Tuesday, January 31st. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $88.56.

Inari Medical Trading Down 1.0 %

NASDAQ NARI opened at $54.09 on Thursday. The stock’s 50 day moving average is $59.73 and its 200 day moving average is $67.95. Inari Medical, Inc. has a 12 month low of $50.50 and a 12 month high of $100.00. The stock has a market cap of $2.94 billion, a PE ratio of -98.34 and a beta of 1.10.

Inari Medical (NASDAQ:NARI – Get Rating) last posted its quarterly earnings results on Monday, February 27th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.06. Inari Medical had a negative return on equity of 7.03% and a negative net margin of 7.63%. The company had revenue of $107.77 million for the quarter, compared to analysts’ expectations of $104.85 million. During the same period in the previous year, the firm earned $0.02 EPS. The firm’s revenue was up 29.5% compared to the same quarter last year. On average, analysts forecast that Inari Medical, Inc. will post -0.48 EPS for the current fiscal year.

Insider Transactions at Inari Medical

In other news, COO Andrew Hykes sold 9,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 20th. The stock was sold at an average price of $68.50, for a total transaction of $616,500.00. Following the sale, the chief operating officer now directly owns 102,998 shares of the company’s stock, valued at approximately $7,055,363. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Mitch C. Hill sold 12,750 shares of the company’s stock in a transaction that occurred on Monday, December 12th. The stock was sold at an average price of $69.58, for a total transaction of $887,145.00. Following the sale, the chief financial officer now directly owns 59,486 shares of the company’s stock, valued at approximately $4,139,035.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Andrew Hykes sold 9,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 20th. The shares were sold at an average price of $68.50, for a total value of $616,500.00. Following the transaction, the chief operating officer now directly owns 102,998 shares in the company, valued at approximately $7,055,363. The disclosure for this sale can be found here. Insiders have sold 196,250 shares of company stock valued at $12,739,010 in the last ninety days. Corporate insiders own 11.90% of the company’s stock.

About Inari Medical

(Get Rating)

Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.